Hemab Therapeutics is focused on creating prophylactic, antibody-based treatments that address the underlying causes of serious bleeding disorders rather than just managing acute events. Its lead asset, sutacimig (formerly HMB-001), has completed Phase 2 in Glanzmann thrombasthenia and is being prepared for a registration study in 2026, with a parallel Phase 2 program planned for Factor VII deficiency. The company’s second clinical candidate, HMB-002, targets the C-terminal CK domain of Von Willebrand Factor to raise endogenous VWF and Factor VIII levels and is advancing toward registration studies in Von Willebrand disease. Backed by its “Hemab 1-2-5” strategy, the team is also moving additional programs forward, with HMB-003 expected to enter the clinic in the first half of 2026. Hemab’s dual headquarters in Cambridge, Massachusetts, and Copenhagen, Denmark, give it access to both U.S. and European scientific ecosystems. The fresh Series C financing provides $157 million to fund late-stage trials, expand the pipeline, and reinforce the company’s goal of becoming “the ultimate clotting company.”

Total raised

$347M

Funding rounds

3

Latest round

Series C

Latest activity

Oct 2025